
Synthetic Defective Interfering Viruses for the Treatment of COVID-19



ID# 2020-5115



DI SARS CoV2 reduces WT replication

Technology Summary

Viruses exploit host cells to produce viral proteins to replicate and infect other cells. The need to produce viral proteins leave viruses susceptible to exploitation by defective versions of themselves. A defective viral genome with deletions in protein-coding genes can replicate in cells coinfected with full-length viruses, but, due to its reduced complexity, the defective virus can replicate faster, out-competing the wild-type virus for resources and attenuating wild-type viral replication. Penn State inventors have created a synthetic defective interfering version of SARS-CoV-2 (DI-SARS-CoV-2).

DI-SARS-CoV-2 does not produce viral proteins and is only able to replicate in cells already infected by the virus. Initial cell culture experiments demonstrate that DI-SARS-CoV-2 replicates three times faster than wild-type in coinfected cells and reducing the wild-type viral load by half in 24 hours. However, without WT virus present, DI-SARS-CoV-2 degrades within hours. Experiments additionally demonstrate that the synthetic genome is transmitted as efficiently as the full-length genome, confirming the retention of required packaging signal. Penn State inventors are currently working to complete reduction to practice in animal models.

Application & Market Utility

Current events highlight the ongoing need for therapies that limit or eliminate infection in those who contract SARS-CoV-2. While DI-mediated viral attenuation has previously been proposed for HIV and Influenza, the Penn State inventors believe that SARS-CoV-2, and more broadly coronaviruses, may be uniquely suited for this strategy due to long single strand RNA genome and relatively simple replication process.

Next Steps

Seeking industry partners to drive pre-clinical and clinical validation.



Invent Penn State is a Commonwealth-wide initiative to spur economic development, job creation, and student career success. Invent Penn State blends entrepreneurship-focused academic programs, business startup training and incubation, funding for commercialization, and university-community collaborations to facilitate the challenging process of turning research discoveries into valuable products and services that can benefit Pennsylvanians and humankind. Learn more at invent.psu.edu.

TECHNOLOGY READINESS LEVEL

Seeking

Research

Keywords

- COVID-19/SARS-CoV-2
- Coronaviruses
- Defective Interfering Viruses
- Synthetic Virus
- Anti-Viral Therapy

Researchers

Marco Archetti Associate Professor of Biology Website

Other Researchers

Originating College Eberly College of Science

Office of Technology Management Contact Long, Melissa mkl137@psu.edu 814-865-5730

Penn State is an equal opportunity, affirmative action employer, and is committed to providing employment opportunities to all qualified applicants without regard to race, color, religion, age, sex, sexual orientation, gender identity, national origin, disability or protected veteran status.